logo
logo
Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc

NASDAQ•AVDL
CEO: Mr. Gregory J. Divis Jr.
セクター: Healthcare
業種: Drug Manufacturers - Specialty & Generic
上場日: 1996-06-07
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
連絡先情報
10 Earlsfort Terrace, Dublin, 2, Ireland
353-1-901-5201
www.avadel.com
時価総額
$2.12B
PER (TTM)
-7558.7
36.6
配当利回り
--
52週高値
$23.57
52週安値
$6.38
52週レンジ
89%
順位71Top 99.6%
1.0
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$77.47M+54.86%
直近4四半期の推移

EPS

$0.00+0.00%
直近4四半期の推移

フリーCF

$23.25M-437.43%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Surges 66.9% Nine-month net product revenue reached $198.11M, driven by LUMRYZ patient uptake, compared to $118.71M last year.
Achieved Net Income Switched to $4.77M net income for nine months, reversing prior $43.79M loss; diluted EPS $0.05.
Jazz Litigation Resolved Settled all Jazz lawsuits; received $90M payment, reversing $9.5M in prior period royalties recorded in COGS.
Cash Position Improved Cash and securities increased $17.80M to $91.58M by September 30, 2025, despite $15M license payment.

リスク要因

Alkermes Transaction Risk Failure to close Alkermes acquisition may cause share price decline and incur significant, non-reimbursable transaction costs.
Intense Product Competition Competitors may launch safer, more effective, or less costly products, diminishing LUMRYZ commercial opportunity or eliminating it.
R&D Expense Surge R&D expenses increased 226.1% for nine months due to $20M upfront license fee for valiloxybate development.
Irish Law Differences Governance under Irish law may afford shareholders less protection during potential takeover offers compared to U.S. standards.

見通し

Alkermes Closing Expected Transaction expected to close in the first quarter of 2026, making Avadel a wholly owned subsidiary of Alkermes plc.
IH Trial Progress Pivotal REVITALYZ trial enrollment expected complete by end of 2025; data submission for supplemental NDA in 2026.
Valiloxybate Development Pursuing global development and commercialization rights for valiloxybate via XWPharma agreement, excluding specific Asian markets.
Tax Law Uncertainty Evaluating impact of new 2025 OBBBA legislation on future tax liabilities; full valuation allowance remains on deferred tax assets.

同業比較

売上高 (TTM)

Organon & Co.OGN
$6.22B
-2.9%
QuidelOrtho CorporationQDEL
$2.73B
-1.9%
Pediatrix Medical Group, Inc.MD
$1.92B
-4.2%

粗利益率 (最新四半期)

Avadel Pharmaceuticals plcAVDL
103.9%
+16.2pp
Zymeworks Inc.ZYME
100.0%
+0.0pp
Dynavax Technologies CorporationDVAX
84.8%
+1.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
GRDN$2.12B51.724.7%8.7%
PAHC$2.12B23.030.8%42.9%
AVDL$2.12B-7558.7-0.3%18.7%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
15.4%
高成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年3月2日
|
EPS:$0.08
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月4日|
    売上高: $77.47M+54.9%
    |
    EPS: $0.00+0.0%
    不明

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $68.13M+64.1%
    |
    EPS: $0.10-171.4%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月7日|
    売上高: $52.51M+93.2%
    |
    EPS: $-0.05-83.3%
    予想を上回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月3日|
    売上高: $169.12M+504.8%
    |
    EPS: $-0.51+74.5%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月12日|
    売上高: $50.03M+613.2%
    |
    EPS: $-0.03-92.7%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月8日|
    売上高: $41.50M+2674.3%
    |
    EPS: $-0.14-83.1%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月8日|
    売上高: $27.18M+0.0%
    |
    EPS: $-0.30-37.5%
    予想を下回る

  • Form 10-K/A - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年4月26日|
    売上高: $27.96M+0.0%
    |
    EPS: $-2.00+12.7%
    予想を下回る